Furthermore, the authors demonstrated that the selective inhibition of VCAM-1 with a neutralising monoclonal antibody (mAb) reduced VCAM-1-mediated leukocyte recruitment and significantly attenuated macroscopic colonic tissue damage and colitis symptoms [50, 55]. This evidence concerns the gene VCAM1 and colitis.